SC
NTLA icon

Scholtz & Company’s Intellia Therapeutics NTLA Stock Holding History

Scholtz & Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,185
Closed -$293K – 68
2021
Q3 		$293K Sell
2,185
-760
-26% -$115K 0.1% 60
2021
Q2 		$477K Buy
+2,945
New +$229K 0.16% 57

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Scholtz & Company's NTLA Position: Q4 2021 in Review

Scholtz & Company sold out of Intellia Therapeutics (NTLA) in Q4 2021, closing a stake of 2,185 shares — an estimated $293K sold.

Scholtz & Company first reported a position in NTLA in Q2 2021 and held it in 2 quarters. The position peaked at $477K in Q2 2021. 371 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • Scholtz & Company reported no remaining Intellia Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Scholtz & Company sold 2,185 Intellia Therapeutics shares in Q4 2021, an estimated $293K.
  • Scholtz & Company first reported a position in Intellia Therapeutics in Q2 2021 and held it in 2 quarters.
  • Scholtz & Company's Intellia Therapeutics position peaked at $477K in Q2 2021.
  • 371 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Scholtz & Company's 13F filing for Q4 2021, filed 15 Feb 2022.